MX2015015341A - Cepas de salmonella para uso en el tratamiento y/o prevencion de cancer. - Google Patents

Cepas de salmonella para uso en el tratamiento y/o prevencion de cancer.

Info

Publication number
MX2015015341A
MX2015015341A MX2015015341A MX2015015341A MX2015015341A MX 2015015341 A MX2015015341 A MX 2015015341A MX 2015015341 A MX2015015341 A MX 2015015341A MX 2015015341 A MX2015015341 A MX 2015015341A MX 2015015341 A MX2015015341 A MX 2015015341A
Authority
MX
Mexico
Prior art keywords
cancer
prevention
treatment
salmonella strains
salmonella enterica
Prior art date
Application number
MX2015015341A
Other languages
English (en)
Inventor
Denise Nardelli Haefliger
Patrice Jichlinski
Sonia Domingos Pereira
Original Assignee
Ct Hospitalier Universitaire Vaudois C H U V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Hospitalier Universitaire Vaudois C H U V filed Critical Ct Hospitalier Universitaire Vaudois C H U V
Publication of MX2015015341A publication Critical patent/MX2015015341A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se relaciona con una composición farmacéutica que comprende un mutante no recombinante atenuado vivo de la cepa de Salmonella entérica serovariedad typhi y/o un mutante no recombinante atenuado no viable de la cepa Salmonella enterica serovariedad typhi para uso en el tratamiento y/o prevención de recurrencia/progreso de cáncer. Preferiblemente, el cáncer es cáncer de vejiga.
MX2015015341A 2013-05-07 2014-05-07 Cepas de salmonella para uso en el tratamiento y/o prevencion de cancer. MX2015015341A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13166851.9A EP2801364A1 (en) 2013-05-07 2013-05-07 Salmonella strain for use in the treatment and/or prevention of cancer
PCT/EP2014/059392 WO2014180929A1 (en) 2013-05-07 2014-05-07 Salmonella strains for use in the treatment and/or prevention of cancer

Publications (1)

Publication Number Publication Date
MX2015015341A true MX2015015341A (es) 2016-06-21

Family

ID=48227075

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015015341A MX2015015341A (es) 2013-05-07 2014-05-07 Cepas de salmonella para uso en el tratamiento y/o prevencion de cancer.

Country Status (7)

Country Link
US (1) US9795641B2 (es)
EP (2) EP2801364A1 (es)
CN (1) CN105377276A (es)
CA (1) CA2910072C (es)
ES (1) ES2903026T3 (es)
MX (1) MX2015015341A (es)
WO (1) WO2014180929A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11642382B2 (en) 2013-12-20 2023-05-09 Seed Health, Inc. Method for treating an individual suffering from bladder cancer
US11672835B2 (en) 2013-12-20 2023-06-13 Seed Health, Inc. Method for treating individuals having cancer and who are receiving cancer immunotherapy
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
EP3922255A1 (en) 2020-06-10 2021-12-15 Prokarium Limited Cancer therapy
WO2022040365A1 (en) * 2020-08-18 2022-02-24 Curators Of The University Of Missouri Compositions and methods of treatment comprising tumor-targeting bacteria and chemotherapy or immunotherapy agent
EP4124342A1 (en) 2021-07-28 2023-02-01 Prokarium Limited Cancer therapy with live attenuated bacteria
WO2024061748A1 (en) 2022-09-21 2024-03-28 Prokarium Limited Salmonella strain with chromosomally integrated landing pad
GB202215576D0 (en) 2022-10-21 2022-12-07 Prokarium Ltd Circuit

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037332A (en) * 1996-02-20 2000-03-14 Emory University Method of urinary bladder instillation
GB9621091D0 (en) * 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
US6962696B1 (en) * 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
US20050180985A9 (en) * 2001-10-04 2005-08-18 Vladoianu Ion R. Live attenuated salmonella strains for producing monovalent or multivalent vaccines
WO2003063593A1 (en) * 2002-01-28 2003-08-07 Vion Pharmaceuticals, Inc. Methods for treating cancer by administering tumor-targetted bacteria and an immunomodulatory agent
US20070298012A1 (en) * 2003-12-16 2007-12-27 Ivan King Compositions and Methods for Tumor-Targeted Delivery of Effector Molecules
WO2005123762A2 (en) * 2004-06-18 2005-12-29 Indian Immunologicals Ltd Codon-optimized hpv16 li for salmonella vaccine strains against human papillomavirus type 16
WO2006076678A2 (en) * 2005-01-13 2006-07-20 The Johns Hopkins University Prostate stem cell antigen vaccines and uses thereof
EP2301535B1 (en) * 2005-09-01 2014-05-28 Celgene Corporation Immunological uses of immunomodulatory compounds for vaccine and anti-infectious disease therapy
CN1974759B (zh) * 2006-07-26 2010-06-09 吉林大学 运载重组质粒的减毒沙门氏菌及其在抗肿瘤中的应用
CN101204584A (zh) * 2007-12-17 2008-06-25 北京娜可长今国际银离子科技开发有限公司 以减毒沙门氏菌为载体的肿瘤疫苗及其制备方法
EP2085466A1 (en) * 2008-01-29 2009-08-05 AEterna Zentaris GmbH Non-pathogenic and/or attenuated bacteria capable of inducing apoptosis in macrophages, process of manufacturing and uses thereof
CA2714276A1 (en) * 2008-02-05 2009-08-13 Aeterna Zentaris Gmbh Recombinant bacteria with e. coli hemolysin secretion system and increased expression and/or secretion of hlya, process of manufacturing and uses thereof

Also Published As

Publication number Publication date
ES2903026T3 (es) 2022-03-30
EP2996699B1 (en) 2021-10-20
CN105377276A (zh) 2016-03-02
EP2801364A1 (en) 2014-11-12
CA2910072A1 (en) 2014-11-13
CA2910072C (en) 2024-01-23
EP2996699A1 (en) 2016-03-23
US9795641B2 (en) 2017-10-24
WO2014180929A1 (en) 2014-11-13
US20160074441A1 (en) 2016-03-17

Similar Documents

Publication Publication Date Title
MX2015015341A (es) Cepas de salmonella para uso en el tratamiento y/o prevencion de cancer.
CO2019000099A2 (es) Composiciones que comprenden cepas bacterianas
MX2017000776A (es) Polipeptidos fhbp meningococicos modificados.
MX2020004419A (es) Polipeptidos fhbp meningococicos modificados.
PH12019501010A1 (en) Arginase inhibitor combination therapies
RS59936B1 (sr) Lactobacillus sojevi sa brzim dejstvom i njihova upotreba za poboljšanje aerobne stabilnosti silaže
PH12017500836A1 (en) Transdermal formulations
RS63856B1 (sr) Probiotički sojevi bakterija za prevenciju i lečenje bolesti u usnoj duplji
MX2016014564A (es) Vacuna contra la acinetobacter baumannii obtenida a partir de componentes celulares carentes de lipopolisacarido.
MX2023010501A (es) Profarmacos de dantroleno y metodos de su uso.
MX2016013631A (es) Celulas huespedes modificadas y usos de las mismas.
CL2012002902A1 (es) Cepas de bacteriofagos especifica contra bacterias pertenecientes al genero vibrio para la profilaxis y terapia de vibrio anguillarum; y composicion antibacteriana que comprende dicha cepas.
IN2015KN00516A (es)
MX2017006019A (es) Apilimod para uso en el tratamiento de melanoma.
IL251687B (en) Medicinal composition for use in treatment to prevent vitamin and mineral deficiencies in patients who have undergone gastric bypass surgery
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
IL260181B (en) Preparations and methods for using new strains of Lactobacillus fermentum
TWD173859S (zh) 電連接器
TWD172410S (zh) 電連接器
MX2018014532A (es) Un metodo para reducir la contaminacion de los huevos.
HUE054877T2 (hu) PRRS legyengített törzse és lehetséges alkalmazása immunizáló készítményekben
AU361187S (en) A physiotherapy apparatus
IN2014DN06739A (es)
AU201614624S (en) Alu sofa of three seaters without arms
CL2014003517A1 (es) Formulación probiótica que comprende cepa de lactobacillus dsm 22105, dióxido de silicio y aceite de colza; proceso preparación; y uso para prevenir y tratar enterocolitis necrotizante en recién nacidos.